Idiosyncratic drug-induced agranulocytosis or acute neutropenia

Current Opinion in Hematology

Volumn 15, Issue 1, 2008, Pages 15-21

  Andrès, Emmanuel ^a,b   Maloisel, Frédéric ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Drug; Hematopoietic growth factor; Idiosyncratic drug induced agranulocytosis; Neutropenia

Indexed keywords

ABACAVIR; AMINOPHENAZONE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTITHYROID AGENT; CAPTOPRIL; CARBAMAZEPINE; CARBIMAZOLE; CARDIOVASCULAR AGENT; CLOZAPINE; COTRIMOXAZOLE; DIGOXIN; DIPYRONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HALOPERIDOL; NAPROXEN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PHENYTOIN; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; SULINDAC; TICLOPIDINE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

AGRANULOCYTOSIS; AWARENESS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EXPOSURE; DRUG INDUCED DISEASE; GRANULOCYTOSIS; GROUPS BY AGE; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LIFE EXPECTANCY; METABOLIC DISORDER; MORTALITY; NEUTROPENIA; NEUTROPHIL COUNT; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; SEPTICEMIA;

ACUTE DISEASE; AGRANULOCYTOSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; INFECTION; NEUTROPENIA; PROGNOSIS; RISK FACTORS; SEPSIS;

EID: 36549023531     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282f15fb9     Document Type: Review

References (39)

1. Schultz W. About specific sore throat [in German]. Dtsch Med Wochenschr 1922; 48:1495-1496.
2. Andrès E, Zimmer J, Affenberger S, et al. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med 2006; 17:529-535.
3. Andersohn F, Konzen C, Garbe E. Nonchemotherapy drug-induced agranulocytosis: A systematic review of case reports. Ann Intern Med 2007; 146:657-665. This is a recent systematic review of all published cases of drug-induced agranulocytosis.
4. Bénichou C, Solal-Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 1993; 33:257-262.
5. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol 2004; 77:316-318.
6. Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenosis, management and avoidance. Drug Safety 1994; 11:445-462.
7. Claas FH. Immune mechanisms leading to drug-induced blood dyscrasias. Eur J Haematol 1996; 60 (Suppl):64-68.
8. Guest I, Uetrecht J. Drugs that induce neutropenia/agranulocytosis may target specific component of the stromal cell extracellular matrix. Med Hypotheses 1999; 53:145-151.
9. Iverson S, Zahid N, Uetrecht JP. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact 2002; 142:175-199.
10. Young NS. Drug-related blood dyscrasias. Eur J Haematol 1996; 60(Suppl):6-8.
11. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphims in drug-induced agranulocytosis. J Clin Psychopharmacol 2004; 24:613-617.
12. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolismdependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58:207-216.
13. Van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159:369-374.
14. Van Staa TP, Boulton F, Cooper C, et al. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 2003; 72:248-254.
15. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165:869-874.
16. Theophile H, Begaud B, Martin K, et al. Incidence of agranulocytosis in Southwest France. Eur J Epidemiol 2004; 19:563-565.
17. Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med 1992; 152:1475-1480.
18. Andrès E, Maloisel F, Kurtz JE, et al. Modern management of nonchemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 2002; 13:324-328.
19. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986; 256:1749-1757.
20. Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study. Clin Pharmacol Ther 1991; 49:330-341.
21. Paitel JF, Stockemer V, Dorvaux V, et al. Acute drug-induced agranulocytosis. Clinical study of 30 patients: evolution of etiologies over 2 decades [in French]. Rev Med Interne 1995; 16:495-499.
22. Vial T, Pofilet C, Pham E, et al. Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years [in French]. Therapie 1996; 51:508-515.
23. Shapiro S, Issaragrisil S, Kaufman DW, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 1999; 60:573-577.
24. Van der Klauw MM, Wilson JH, Stricker BH. Drug-associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am J Hematol 1998; 57:206-211.
25. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 1996; 60 (Suppl):23-30.
26. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a nonjewish caucasian sample. Arch Gen Psychiatry 2001; 58:93-94.
27. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Hematol 1991; 79:366-372.
28. Maloisel F, Andrès E, Kaltenbach G, et al. Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med 2004; 33:1164-1168.
29. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150:621-624.
30. Tajiri J. Antithyroid drug-induced agranulocytosis: special reference to normal white cell count agranulocytosis. Thyroid 2004; 14:459-462.
31. Andrès E, Noel E, Kurtz JE, et al. Life-threatening idiosyncratic druginduced agranulocytosis in elderly patients. Drugs Aging 2004; 21:427-435.
32. Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Safety 2003; 26:691-706.
33. Andrès E, Kurtz JE, Martin-Hunyadi C, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 2002; 112:460-464.
34. Andrès E, Kurtz JE, Perrin AE, et al. The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients. Q J Med 2001; 94:423-428.
35. Sprikkelman A, de Wolf JTM, Vellenga E. Application of haematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 1994; 8:2031-2036.
36. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 1999; 19:299-305.
37. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroïd 1999; 9:29-31.
38. Andrès E, Noel E, Maloisel F. Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis. Am J Med 2004; 116:354.
39. Bhatt V, Saleem A. Drug-induced neutropenia: pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004; 34:131-137.